Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  The Prostate

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pros.20310PMID 16161153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erythropoietin and erythropoietin receptor expression in human prostate cancer

  2005cited by this paper
• Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line

  2004cited by this paper
• Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells

  2004cited by this paper
• Interactions of a herbal combination that inhibits growth of prostate cancer cells

  2004cited by this paper
• Beneficial and ominous aspects of the pleiotropic action of erythropoietin

  2004cited by this paper
• Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis.

  2004cited by this paper
• Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells.

  2004cited by this paper
• Epothilone induced cytotoxicity is dependent on p53 status in prostate cells

  2004cited by this paper
• Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP

  2004cited by this paper
• Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells

  2004cited by this paper
• VIP and PACAP are autocrine factors that protect the androgen‐independent prostate cancer cell line PC‐3 from apoptosis induced by serum withdrawal

  2003cited by this paper
• Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system.

  2003cited by this paper
• Pleiotrophic actions of erythropoietin

  2003cited by this paper
• Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells*

  2003cited by this paper
• Expression of erythropoietin receptor splice variants in human cancer.

  2003cited by this paper
• Erythropoietin regulates tumour growth of human malignancies.

  2003cited by this paper
• BCL-2 and BCL-XL Restrict Lineage Choice during Hematopoietic Differentiation*

  2003cited by this paper
• Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia‐Reperfusion Injury

  2003cited by this paper
• Activation of extracellular signal‐regulated kinases ERK1 and ERK2 induces Bcl‐xL up‐regulation via inhibition of caspase activities in erythropoietin signaling

  2003cited by this paper
• Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumor Cell Survival

  2003influential reference
• Intermediate basal cells of the prostate: In vitro and in vivo characterization

  2003cited by this paper
• Breast cancer trial with erythropoietin terminated unexpectedly.

  2003cited by this paper
• Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice.

  2003cited by this paper
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

  2003cited by this paper
• Normal and neoplastic prostate cells have EPO receptors.

  2003cited by this paper
• Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

  2003cited by this paper
• Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer.

  2003cited by this paper
• Bcl-XL is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its antiapoptotic function.

  2003cited by this paper
• Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts.

  2002cited by this paper
• Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs.

  2002cited by this paper
• EPO's Alter Ego: Erythropoietin Has Multiple Actions

  2002cited by this paper
• Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma

  2002cited by this paper
• Functional Significance of Erythropoietin Receptor Expression in Breast Cancer

  2002cited by this paper
• Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

  2002cited by this paper
• Erythropoietin – a novel concept for neuroprotection

  2001cited by this paper
• Pleiotropic functions and tissue-specific expression of erythropoietin.

  2001cited by this paper
• Correction of Cancer Anemia – Impact on Disease Course, Prognosis and Treatment Efficacy, Particularly for Patients Undergoing Radiotherapy

  2001cited by this paper
• Erythropoietin and erythropoietin receptor expression in human cancer.

  2001influential reference
• Anemia treatment and the radiation oncologist: optimizing patient outcomes.

  2001cited by this paper
• Expression of erythropoietin in human female reproductive organs.

  2001cited by this paper
• Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice

  2001cited by this paper
• Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts.

  2001cited by this paper
• Erythropoietin acts as a trophic factor in neonatal rat intestine

  2001cited by this paper
• Effects of epoetin alfa on the central nervous system.

  2001cited by this paper
• Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.

  2001cited by this paper
• Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.

  2001cited by this paper
• The negative impact of anemia on radiotherapy and chemoradiation outcomes.

  2001cited by this paper
• Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.

  2001cited by this paper
• Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

  2001cited by this paper
• Erythropoietin in radiation oncology - A review. 1st international conference, Freiburg, June 11-12, 1999.

  2000cited by this paper
• Erythropoietin-Inducible Immediate-Early Genes in Human Vascular Endothelial Cells

  2000cited by this paper
• Erythropoietin in Radiation Oncology – A Review

  2000cited by this paper
• Differential involvement of the Fas receptor/ligand system in p53‐dependent apoptosis in human prostate cancer cells

  2000cited by this paper
• Erythropoietin Receptors That Signal Through Stat5 or Stat3 Support Fetal Liver and Adult Erythropoiesis: Lack of Specificity of Stat Signals During Red Blood Cell Development

  2000cited by this paper
• Endothelium‐derived factors as paracrine mediators of prostate cancer progression

  2000cited by this paper
• Clinical Applications of Recombinant Human Erythropoietin

  2000cited by this paper
• The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner.

  2000cited by this paper
• Activation of STAT5 during EPO-directed suppression of apoptosis.

  2000cited by this paper
• Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation.

  2000cited by this paper
• Role of procathepsin D activation peptide in prostate cancer growth

  2000cited by this paper
• Cadmium and platinum suppression of erythropoietin production in cell culture: clinical implications.

  2000cited by this paper
• Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight.

  2000cited by this paper
• Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

  2000cited by this paper
• Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.

  2000cited by this paper
• Chemotherapy-induced anemia in adults: incidence and treatment.

  1999cited by this paper
• GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression.

  1999cited by this paper
• Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

  1999cited by this paper
• Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line

  1999cited by this paper
• Erythropoietin Can Induce the Expression of Bcl-xLthrough Stat5 in Erythropoietin-dependent Progenitor Cell Lines*

  1999cited by this paper
• Immunohistochemical Localization of Erythropoietin and Its Receptor in the Developing Human Brain

  1999cited by this paper
• Cancer progression.

  1999cited by this paper
• Why Is Erythropoietin Present in Human Milk? Studies of Erythropoietin Receptors on Enterocytes of Human and Rat Neonates

  1999cited by this paper
• Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction.

  1999cited by this paper
• Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors.

  1998cited by this paper
• Estrogen-dependent Production of Erythropoietin in Uterus and Its Implication in Uterine Angiogenesis*

  1998cited by this paper
• Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.

  1998cited by this paper
• Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.

  1997cited by this paper
• Models for cancer skeletal metastasis: a reappraisal of Batson's plexus.

  1997cited by this paper
• Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase C-dependent pathway in human erythropoietin-dependent cell line AS-E2.

  1997cited by this paper
• Radiation-induced neoplastic transformation of human prostate epithelial cells.

  1996cited by this paper
• Association of JAK2 and STAT5 with Erythropoietin Receptors

  1996cited by this paper
• Recombinant human erythropoietin stimulates angiogenesis in vitro.

  1995cited by this paper
• Regulated production of a pleiotropic cytokine-platelet-derived growth factor--by differentiating erythroid cells in vitro and in vivo.

  1995cited by this paper
• Erythropoietin receptor mRNA expression in human endothelial cells.

  1994cited by this paper
• Pattern of prostate cancer metastasis to the vertebral column

  1994cited by this paper
• Neoplastic transformation of a human prostate epithelial cell line by the v‐Ki‐ras oncogene

  1993cited by this paper
• Antipeptide antibodies as probes of the recombinant and endogenous murine erythropoietin receptors.

  1993cited by this paper
• Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells.

  1993cited by this paper
• Clinical significance of the vertebral vein in prostate cancer metastasis.

  1992cited by this paper
• Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation.

  1992cited by this paper
• Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.

  1990cited by this paper
• Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism.

  1990cited by this paper
• Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.

  1990cited by this paper
• Characterization of biologically active, platelet-derived growth factor-like molecules produced by murine erythroid cells in vitro and in vivo.

  1990influential reference
• Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes.

  1989cited by this paper
• Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone‐stimulated growth and drug‐induced cytostatic and cytotoxic effects

  1988cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• LNCaP model of human prostatic carcinoma.

  1983influential reference
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979influential reference
• [Cancer cells].

  1950cited by this paper

• Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling

  2024cites this paper
• Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

  2021cites this paper
• Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo

  2020cites this paper
• Erythropoietin Signaling in the Microenvironment of Tumors and Healthy Tissues.

  2020cites this paper
• CYTOKINES, JAK-STAT SIGNALING AND RADIATION-INDUCED DNA REPAIR IN SOLID TUMORS: NOVEL OPPORTUNITIES FOR RADIATION THERAPY.

  2020cites this paper
• Involvement of STAT5 in Oncogenesis

  2020cites this paper
• The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

  2020cites this paper
• Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA‐23a‐AKT signaling in hepatocellular carcinoma

  2020cites this paper
• A novel copper (II) PAmPiCaT complex (cPAmPiCaTc) as a biologically potent candidate: A contraption evidence against methicillin-resistant Staphylococcus aureus (MRSA) and a molecular docking proof.

  2019cites this paper
• Anemia of cancer in a spontaneously breast cancer developing mouse model

  2019cites this paper
• Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer

  2019cites this paper
• Simultaneous use of erythropoietin and LFM‐A13 as a new therapeutic approach for colorectal cancer

  2018cites this paper
• Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer

  2018cites this paper
• Preclinical development of anticancer Ru-based nanoaggregates in breast cancer models

  2017cites this paper
• IN VITRO BIOLOGICAL ACTIVITY ASSESSMENT OF RHEPO PHARMACEUTICAL FORMULATIONS FOR BATCH RELEASE

  2017cites this paper
• No erythropoietin-induced growth is observed in non-small cell lung cancer cells.

  2017cites this paper
• Significance of Erythropoietin Receptor Antagonist EMP9 in Cancers.

  2017cites this paper
• Erythropoietin, Stem Cell Factor, and Cancer Cell Migration.

  2017cites this paper
• Erythropoietin Concomitantly with Ethinyl Estradiol can Cause Uterine and Ovarian Cancers

  2017cites this paper
• The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.

  2016cites this paper
• Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles

  2016cites this paper
• Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts

  2016cites this paper
• Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia

  2015cites this paper
• Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

  2015cites this paper
• hematology Board review manual Cancer-related anemia

  2015cites this paper
• Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

  2014cites this paper
• Systematic Review: The Association and Impact of Financial Conflicts of Interest in Basic Science Research

  2014cites this paper
• Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

  2013cites this paper
• Layered Signaling Regulatory Networks Analysis of Gene Expression Involved in Malignant Tumorigenesis of Non-Resolving Ulcerative Colitis via Integration of Cross-Study Microarray Profiles

  2013cites this paper
• Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

  2013cites this paper
• Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer

  2013cites this paper
• Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis

  2013cites this paper
• Human erythropoietin increases the pro-angiogenic potential of A2780 ovarian adenocarcinoma cells under hypoxic conditions.

  2013cites this paper
• The effect of erythropoietin on normal and neoplastic cells

  2012cites this paper
• Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development

  2012cites this paper
• The Role of Erythropoietin and its Receptor in Growth and Survival of non-small cell Lung Cancer cells

  2012influential citation
• Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities.

  2012cites this paper
• Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

  2011cites this paper
• Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models

  2011cites this paper
• Immunhistochemische Untersuchung zur Erythropoietin-Rezeptor-Expression in humanen kolorektalen Karzinomen und deren Korrelation mit dem Patienten-Überleben

  2011cites this paper
• Erythropoietin receptor expression in normal and neoplastic choroid plexus.

  2011cites this paper
• Constitutively Active Soluble Form of Erythropoietin Receptor Suppresses Growth and Angiogenesis of Xenografts of Transfected Cancer Cell Lines

  2011cites this paper
• Erythropoietin.

  2011cites this paper
• The Neurobiology of Erythropoietin

  2011cites this paper
• Preclinical Development Transcription Factor Stat 5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

  2011cites this paper
• Pleiotropic effects of erythropoietin

  2011cites this paper
• Randomized controlled trials of the erythroid-stimulating agents in cancer patients.

  2011cites this paper
• Tumorigenesis and Neoplastic Progression RNA Interference-Mediated Inhibition of Erythropoietin Receptor Expression Suppresses Tumor Growth and Invasiveness in A 2780 Human Ovarian Carcinoma Cells

  2010cites this paper
• Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

  2010cites this paper
• Editorial comment.

  2010cites this paper
• Recombinant Human Erythropoietin (rHuEPO) In Combination with Chemotherapy Increases Breast Cancer Metastasis In Pre-Clinical Mouse Models

  2010cites this paper
• Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment

  2010cites this paper
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

  2010cites this paper
• Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents

  2010cites this paper
• The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.

  2010cites this paper
• Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissue.

  2010cites this paper
• Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line

  2010cites this paper
• [The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: beyond anaemia].

  2009cites this paper
• Impact of erythropoietin on the effects of irradiation under hypoxia

  2009cites this paper
• An Erythropoietin Autocrine/Paracrine Axis Modulates the Growth and Survival of Human Prostate Cancer Cells

  2009cites this paper
• Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.

  2009cites this paper
• RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.

  2009cites this paper
• Erythropoietin receptor is expressed in meningiomas and lower levels are associated with tumour recurrence

  2009cites this paper
• Nonhematopoietic effects of erythropoiesis-stimulating agents

  2009influential citation
• Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.

  2009cites this paper
• Biological functions and therapeutic use of erythropoiesis‐stimulating agents: perplexities and perspectives

  2009cites this paper
• How Might ESAs Alter Cancer Biology , Response to Treatment , or Survival ?

  2009cites this paper
• Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

  2009cites this paper
• Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals.

  2008cites this paper
• Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells

  2008cites this paper
• Erythropoietin in heart and vessels: focus on transcription and signalling pathways

  2008cites this paper
• Einsatz von Erythropoese-stimulierenden Proteinen bei anämischen Patienten mit malignen Erkrankungen

  2008cites this paper
• Hypoxia-associated markers in gastric carcinogenesis and HIF-2α in gastric and gastro-oesophageal cancer prognosis

  2008cites this paper
• Beyond Anemia: The Clinical Impact of the Physiologic Effects of Erythropoietin

  2008cites this paper
• Problems associated with erythropoietin receptor determination on tumor cells

  2008cites this paper
• Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells

  2008cites this paper
• Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells

  2008cites this paper
• The erythropoietin receptor in normal and cancer tissues.

  2008cites this paper
• Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia

  2008cites this paper
• Erythropoietin-stimulating agents in oncology.

  2008cites this paper
• Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.

  2008cites this paper
• Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed

  2008cites this paper
• embrane-initiated steroid action in breast nd prostate cancer

  2008cites this paper
• Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives

  2008cites this paper
• Running title : Epo regulation of adhesion / migration factors

  2007cites this paper
• Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.

  2007cites this paper
• Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and Progression

  2007cites this paper
• Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6

  2007cites this paper
• Impaired Downregulation Following Erythropoietin Receptor Activation in Non‐Small Cell Lung Carcinoma

  2007cites this paper
• Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway

  2007cites this paper
• Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence

  2007cites this paper
• Increased expression of erythropoietin receptor in human pterygial tissues.

  2007cites this paper
• Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis

  2007cites this paper
• Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?

  2007cites this paper
• Lack of functional erythropoietin receptors of cancer cell lines

  2007cites this paper
• Expression and function of erythropoietin receptors in tumors

  2007cites this paper
• Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells

  2007cites this paper
• Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non–Small Cell Lung Cancer

  2007cites this paper
• BACKGROUND INFORMATION FOR ONCOLOGIC DRUGS ADVISORY COMMITTEE

  2007influential citation
• Functional significance of erythropoietin receptor on tumor cells.

  2006influential citation